RGNX +28% on potential milestones/royalties from AVXS for use of RGNX’s vectors, pursuant to agreements struck in 2014 and 2017 (amended in Jan 2018): http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=irol-newsArticle&ID=2083032 http://investors.avexis.com/phoenix.zhtml?c=254285&p=irol-newsArticle&ID=2279618 http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=irol-newsArticle&ID=2325394